Vertex to Acquire Crinetics for $10 Billion Cash at 102% Premium
CRNX•Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion in cash, representing a 102% premium to its prior trading price. The deal grants Vertex rights to Palsonify, a once-daily oral therapy for acromegaly targeting an estimated 20,000 U.S. patients.
1. Acquisition Terms
Vertex agreed to pay $10 billion in cash to acquire all outstanding shares of Crinetics Pharmaceuticals, valuing the deal at a 102% premium to the company’s closing price before the announcement. The transaction remains subject to customary regulatory approvals and is expected to close later in 2026.
2. Palsonify Therapy
Palsonify is an oral, once-daily treatment for acromegaly, a rare pituitary disorder affecting roughly 20,000 patients in the U.S. The therapy offers a convenient at-home alternative to existing injectable regimens, with the potential to improve patient adherence and outcomes.
3. Strategic Rationale
The acquisition strengthens Vertex’s endocrine and rare disease portfolio by adding a high-value, differentiated oral asset. It aligns with a broader industry trend valuing therapies that simplify dosing schedules and reduce treatment friction for patients.
